GlassScriptPhysician profile
Patrick Kindregan
NPI 1821436999
$6,232.45
in general payments reported to CMS, 2019-2025
36 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $583 · 2021: $746 · 2022: $714 · 2023: $1,201 · 2024: $1,108 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,070 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,070.04 |
| Education | $302.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $954.22 | 2019-2025 | |
| Astellas Pharma US INC | $811.40 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $540.03 | 2019-2025 | |
| Lilly USA, LLC | $539.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $445.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $429.56 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $422.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.41 | 2019-2024 | Ofev |
| Amgen INC. | $202.02 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $162.94 | 2020-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $140.00 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $130.56 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $114.92 | 2019-2021 | |
| Medtronic, INC. | $114.21 | 2024-2025 | Interstim, Intellis Adaptivestim |
| Abbott Laboratories | $103.14 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Kindregan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.